You are here:

Forthcoming Submission: empaglifozin linagliptin fixed-dose combination (Glyxambi)

Indication: Indicated in adults aged 18 years and older with type 2 diabetes mellitus: • to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control • when already being treated with the free combination of empagliflozin and linagliptin

Drug Details

Drug Name: empaglifozin linagliptin fixed-dose combination (Glyxambi)
Drug Manufacturer: Boehringer Ingelheim Ltd
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission type: Abbreviated Submission
SMC Meeting Date: 4/04/2017
Advice Due: TBC